The acute hepatic porphyrias which comprise acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria are examples of pharmacogenetic disease. They are the result of deficiencies of individual enzymes in the pathway of haem biosynthesis and are inherited in an autosomal dominant fashion.2 Subjects with the genetic trait generally enjoy good health but are at risk of developing severe and life threatening attacks of porphyria if exposed to certain commonly prescribed drugs. Prevention of such attacks depends upon identifying subjects with the genetic trait and preventing them from being exposed to porphyrinogenic drugs. As a result of family screening programmes there has been a marked increase in the number of subjects known to have porphyria and a significant proportion of them will require treatment with anti-inflammatory agents at some time in their life. To 
Results
The effects of the various drugs on hepatic ALA synthase activity are shown in Table 1 . Phenobarbitone resulted in a 214% increase in enzyme activity (p<0.01). Of the eight first line non-steroidal antiinflammatory drugs studied, only azapropazone significantly affected ALA synthase activity, increasing it by 55% (p<005). Of the four second line agents studied, gold increased ALA synthase activity by 56% (p<0-05) and chloroquine increased it by 71% (p<0-05). ALA synthase activity was not affected by prednisolone or penicillamine. In the animal studies the drug is administered in a dose which is slightly higher than the human dose as false negative results are potentially more damaging to the patients. The drugs are administered to animals by intraperitoneal injection as we have found this to be the only reliable way of being certain that the full dose has been received. Hepatic ALA synthase activity is measured three days after the initial dose as this is the time at which any increase in the enzyme activity will be most marked. 6 The inclusion of a porphyrinogenic drug, such as phenobarbitone, in the animal studies provides confirmation of the validity of the model and also permits some measurement of the porphyrinogenicity of the drugs being tested relative to the standard.
The finding that azapropazone, chloroquine, and gold increase hepatic ALA synthase activity indicates that these drugs are liable to result in exacerbations of acute porphyria. The degree of increase in enzyme activity with these drugs was less than with phenobarbitone, indicating that they are less potent porphyrinogenic agents. The other drugs tested did not affect ALA synthase and should be safe to use in patients with porphyria. Some caution is required, however, when applying results of animal studies to humans as different species may vary in their response to inducing agents.
There is currently considerable concern about the many adverse effects of anti-inflammatory agents. The elucidation of the biochemical basis of drug induced attacks of porphyria has meant that this particular adverse effect can be predicted and prevented. Hopefully this will also soon be true of some of the other adverse effects of these agents. 
